| abstract |
The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from any activity-compromising steric hindrance caused by the half-life enhancing polypeptide and, thereby, allows the generation of fusion proteins with high molar specific activity. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after cleavage respectively activation compared to the corresponding therapeutic fusion protein without cleavable linker. |